Following competitor Novartis, pharma giant Roche also announces massive investments in the United States. Swiss jobs and ...

With a market cap of $775.6 billion, Eli Lilly and Company (LLY) is a global biopharmaceutical leader with leading products ...

Novo Nordisk, maker of Ozempic, applied for FDA approval for a weight loss pill, less than a week after rival Eli Lilly's clinical trial success.

Next on the list of largest golden parachutes is Gilead’s Daniel O’Day, who would receive $80.6 million in the event of ...

UnitedHealth Group spent nearly $1.7 million on security for its top executives in 2024, the healthcare conglomerate ...

When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects.

Adults with overweight or obesity plus prediabetes maintain most of their weight loss with tirzepatide at more than 3 years, ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Many novel drugs are more relevant for subspecialists, but of the six first-in-class medications approved by the US Food and ...

Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of ...

Novo Nordisk filed for approval of an oral, 25-mg formulation of semaglutide “earlier this year,” according to a company spokesperson.

ZURICH] Roche said on Tuesday (Apr 22) it would invest US$50 billion in the United States over the next five years, creating ...